Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 May 30;25(6):1073–1082. doi: 10.1038/s41590-024-01833-w

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2024, corrected publication 2024

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Extended Data Fig. 10 — a, Percentage of GC B cells (CD38⁻CD71⁺) among all B cells (CD3⁻CD20⁺) in fine needle aspirate samples of rhesus macaques 3 or 10 weeks post immunization with 10E8-GT10.2 12mer, as described in Fig. 7. Each symbol represents an independent lymph node (n = 16 from n = 8 independent animals). b, Frequency of epitope-specific (10E8-GT10.2⁺⁺10E8-GT10.2-KO⁻) GC B cells (CD38⁻CD71⁺) observed as a percentage of total B cells (CD3⁻CD20⁺) 2 weeks prior to or 3 or 10 weeks post immunization with 10E8-GT10.2 12mer, as described in Fig. 7. Each symbol represents an independent lymph node (n = 8 for week −2, n = 16 for week 3 and 10). c, Median percent amino acid (aa) mutations in the V_H of epitope-specific (10E8-GT10.2⁺⁺10E8-GT10.2-KO⁻or 10E8-GT12⁺⁺10E8-GT12-KO⁻) BCRs sorted from macaques immunized with 10E8⁻GT10.2 12mer or 10E8-GT12 12mer at the indicated time-points from GC B cells (CD38⁻CD71⁺) or PBMC-memory B cells (CD20⁺IgD⁻) among BCRs with 10E8-class HCDR3s (10E8-class) compared to BCRs lacking the YxFW motif (Competitor). Symbols represent individual animals, bars indicate median values. d, SPR-measured monovalent K_D values for 10E8-GT10.2 binding to selected antibodies with 10E8-class HCDR3s (10E8-class) or lacking the YxFW motif (Competitor) induced by 10E8-GT10.2 12mer isolated from the GCs at week 3 (W3) or 10 (W10) post immunization, compared to available matching inferred-germline (iGL) antibodies. Each symbol represents one antibody. e, SPR-measured monovalent K_D values for 10E8-GT10.2 binding to selected mutated or unmutated antibodies with 10E8-class HCDR3s (10E8-class) or lacking the YxFW motif (Competitor) induced by 10E8-GT10.2 12mer isolated from PBMC-memory (CD20⁺IgD⁻). f, Frequency of 10E8-class IgH among PBMC-memory B cells (CD20⁺IgD⁻) at week 11 (GT10.2, n = 6) or week 10 (GT12, n = 5) post immunization compared to macaques immunized with stabilized soluble HIV envelope protein (control, week 10, n = 4). For comparison, dotted lines indicate median frequencies of VRC01-class precursors 8 weeks after high dose (HD) or low dose (LD) immunization with eOD-GT8 60mer in the IAVI G001 human phase 1 clinical trial⁵, with the caveat that frequencies in G001 were measured among IgG⁺ B cells rather than IgD⁻B cells. Open symbols indicate macaques lacking a permissive D_H3-41 allele. Lines indicate median values.